Aduhelm Approval Is Breakthrough For Neurimmune, Company Which Discovered It
Royalties Will Fuel R&D Expansion
Executive Summary
The co-founder of the Swiss company which discovered aducanumab looks back over its 20 year wait for approval, and ahead to future growth plans.
You may also be interested in...
Biogen Closes The Book On The Aduhelm Saga
Biogen will end the development and commercialization of Aduhelm, the first anti-amyloid antibody drug to reach the US market for Alzheimer’s, including the confirmatory ENVISION trial. Product’s legacy includes an FDA that appears less enthusiastic about accelerated approvals for large indications and a CMS that is more interested in label-driven reimbursement decisions.
Biogen Closes The Book On The Aduhelm Saga
Biogen will end the development and commercialization of Aduhelm, the first anti-amyloid antibody drug to reach the US market for Alzheimer’s, including the confirmatory ENVISION trial.
Without An Alzheimer’s Blockbuster, Biogen Is A Ship Without A Growth Rudder
In addition to its uncertain attempt at near-term revenue growth with Eisai-partnered lecanemab, Biogen recently ended multiple R&D programs and will pay $900m to settle a whistleblower lawsuit.